LDUNA Aesthetics and Wellness Center Grand Opening Celebration, Jan. 22 – Nevada Business Magazine

What: LDUNA Aesthetics and Wellness Center, designed to explore and introduce the future of advance treatments for the purposes of anti-aging, wellness, and aesthetics, is hosting a grand opening celebration on Jan. 22. Recognized astheCenter of Excellence for Merakris Therapeutics, a biotechnology company that focuses on cellular regeneration, Ldunasprocess will help to empower a healthier, happier, and improved quality of life.The event will feature jazz entertainment byNieve Malandra, delicious bites by Chef Anthony Vidal, 30-40% off treatments booked that evening, and raffle prizes.

Our centers approach to non-surgical procedures and regenerative treatments to enhance and restore youthfulness will not only change the way others see you, but the way you see yourself. says Byron Brooks,Director of Operations at Lduna Aesthetics and Wellness Center. We are grateful to the Henderson community for welcoming us and look forward to working with Henderson Leadership and community members to sponsor and support community activities and initiatives.

The med spas aesthetics category provides the most innovative, non-surgical methods of skin tightening for both the face and body. These services include Botox, Kybella, Juvederm, and other known fillers, Plasma Pen, as well as, fat cell reduction body contouring, laserskin improvement treatments, micro-needling with exosomes, and other technological skin related services. The anti-aging services offered are genetic testing and bio-identical hormone replacement therapy, to ensure peak biological performance, while Ldunasregenerative medicine category includes the following treatments: Platelet Rich Plasma (PRP), exosome therapy, and joint mobility injections.

Additionally, LDUNAs line of featured luxury products include: Cosmedix, Lucrece, Valmont, GM Collin, NeoCutis, and Jan Marini.

When: Wednesday, January 22

Time: 5:30pm

Address: 10521 Jeffreys Street, Henderson, Suite 220, 89052

Who: Byron Brooks, Director of Operations

Dr. Bonnie Fraser, and Dr. Abraham Fakhouri, Medical Directors

Debra Newell,Celebrity Interior Designer, Featured on Netflix and Bravo

Nieve Malandra, Entertainment/Singer

Chef Anthony Vidal

Zach Zoufaly,Chippendales Performer

For more information, please visit:https://lduna.com/(in development) or like and share on Facebook atLduna Aesthetics and Wellness Center.

More here:
LDUNA Aesthetics and Wellness Center Grand Opening Celebration, Jan. 22 - Nevada Business Magazine

Hair VitaminsHow to Choose the Best Hair Vitamins and How Long Do You Have to Take Them? – Parade

Im stepping into 2020 with the healthiest hair Ive ever had, beauty influencer Brittanie Evans recently posted on Instagram, touting her partnership with SugarBearHair supplements. Celebrities like Kylie Jenner, Vanessa Hudgens and Gwyneth Paltrow have also credited hair vitamins for their luxurious locks.

But, do hair vitamins actually work? It depends, says New Orleans-based dermatologist Mary Lupo.

She compares hair supplements to chicken soupthey cant really hurt and may help. But, if you have a medical condition causing hair loss or other hair issues, hair vitamins likely wont help, and medical treatment may be needed.

What I think is important is that a person kind of go through a little checklist and make sure that before they spend money on vitamins, that theyve ruled out other things that can cause the problem, she says.

You may wish your hair was thicker or shinier or that it would grow longer more quickly. There are several reasons why your hair may not be cooperating.

Stress is a big one: Cortisol is your stress hormone, and a lot of women lose hair or shed hair, or their hair doesnt grow as long because of stress, Lupo says.

Stress can cause a condition called telogen effluvium, a scalp disorder that leads to hair shedding or thinning. It often occurs after instances of stress on the body, like surgery, illness or having a baby, Lupo says.

Other reasons you have issues with your hair:

Some conditions actually damage the hair follicle, Lupo says. Cicatricial alopecia, for example, is caused by scar tissue in the hair follicle, making hair fall out, and its usually irreversible. Alopecia areata is an autoimmune disease, causing quarter-sized chunks of hair to fall out.

Genetics also play a role in hair loss or conditions that cause it.

Hair loss because of chemotherapy could benefit from hair vitamins, Lupo says.

When you have hair loss from chemo, your hair has to cycle back and maybe the hair vitamins can speed it up a little bit, she says. I dont think its going to be anything earth-shattering, but I dont think it would hurt and it might help a little bit.

Related: Everything You Need to Know About Hair Extensions

For someone without a medical condition, vitamins could improve hair, but it will take time, six months or more to see a result, Lupo says. Thats because hair follicles grow in cycles.

According to the Cleveland Clinic, the anagen, or growing, phase, may last two to eight years, and refers to most of the hair you have. The catagen phase, which takes two to three weeks, refers to the timeframe when hair follicles shrink. The telogen, or resting, phase is when the hair falls out and can take two to four months.

If your hair cycles into the telogen phase too quickly, it may not grow as long as youd like, since once the hair sheds, and the process starts all over again, Lupo says. Seeing results from hair vitamins depends on taking them regularly for several months.

One month isnt going to make any difference at all, she says. Then, once you see the result, what I tell my patients is you can lower the dose of the vitamin. Like if it tells you to take four a day, you could cut it down to two a day or whatever as a maintenance dose after youve taken it for about a year. But, dont discontinue it or youll lose the benefit.

When shopping for hair vitamins, read the list of ingredients to ensure they contain substances that promote healthy hair: B vitamins, especially biotin, and vitamin E promote hair, nail and skin health, Lupo says.

The way vitamins help hair is really more from the antioxidant or anti-inflammatory (standpoint) to make the scalp healthier and the hair follicle healthier, she explains.

Many hair vitamins also contain plant-based ingredients, like ashwagandha and saw palmetto, which encourage hair health.

Ashwagandha has been shown to lower cortisol and also has anti-inflammatory properties, which promotes healthy hair. Saw palmetto is an ingredient in may products for men that helps with hair loss and prostate cancer.

Related: Is Hairprint the Secret to Covering Your Gray Naturally?

The U.S. Food and Drug Administration(FDA) does not review supplements, including hair vitamins, for safety before theyre allowed on the market. Lupo says hair vitamins are generally safe, though.

She suggests reviewing a hair vitamin products list of ingredients and choosing ones without too many additives. Also, look for ones that are Good Manufacturing Practice (GMP) certified, like the Natures Bounty brand.

Finally, be wary of any hair vitamins that make medical or any too-good-to-be-true claims.

I think that theyre safe for anybody, Lupo says. Its just the danger is if you have a medical condition that is undiagnosed and unrecognized that is causing you to lose your hair. If youre just taking vitamins, you might be wasting your time and your money, and youre not getting a proper diagnosis so that you can get appropriate treatment.

Along with hair vitamins, prescription drugs like Propecia and Rogaine can help treat hair loss, Lupo says, but women shouldnt take Propecia unless they are postmenopausal.

Dermatologists may also use platelet-rich plasma (PRP) therapy injections to trigger hair follicles to grow more hair. Lupo says usually four to six sessions of PRP are needed, and need to be repeated after several months to maintain results.

PRP is pretty much considered the gold standard of a therapeutic option, Lupo says. Its perfectly safe because you take your own blood, its spun down, you extract the platelets, and its injected into the scalp.

Diet also improves hair quality. Eating plenty of protein, omega-3 fatty acids, and fruits and vegetables, especially dark green veggies, can make your hair thicker and shinier.

If you have hair loss, thinning or other problems, Lupo suggests visiting your dermatologist to rule out any medical problems, even before trying hair vitamins or if youve tried hair vitamins with no results.

I would urge a person if theyve got a real hair loss problem to get the appropriate evaluation by a dermatologist and any recommended blood work that the dermatologist gives you sooner rather than later, she says.

Tempted to try a lash lift? Check out our guide.

Read this article:
Hair VitaminsHow to Choose the Best Hair Vitamins and How Long Do You Have to Take Them? - Parade

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of…

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardias large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005200/en/

"BlueRock is a leader in the field of cell therapy and our collaboration is a perfect match of mission and capabilities. This relationship allows us to utilize our experience in iPSC process development to help advance potential cell therapies for cardiac diseases," said Stefan Braam, CEO of Ncardia.

"There are hundreds of millions of people worldwide that suffer from degenerative cardiovascular disease where the root cause is the loss of healthy heart muscle cells, and where medical treatment options are limited. BlueRocks authentic cellular therapy is a novel approach that has the potential to transform the lives of patients, but will require the manufacture of our cell therapies at unprecedented scale. The Ncardia team has developed key technologies related to this scale-up challenge, and we are pleased to work with them as we advance BlueRocks novel CELL+GENE platform towards the clinic and those patients in need," said Emile Nuwaysir, President and CEO, BlueRock Therapeutics.

About BlueRock Therapeutics

BlueRock Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics CELL+GENE platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics cell differentiation technology recapitulates the cells developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRocks culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit http://www.bluerocktx.com.

About Ncardia

Ncardia believes that stem cell technology can deliver better therapies to patients faster. We bring cell manufacturing and process development expertise to cell therapy by designing and delivering human induced pluripotent stem cell (iPSC) solutions to specification. Our offerings extend from concept development to pre-clinical studies, including custom manufacturing of a range of cell types, as well as discovery services such as disease modelling, screening, and safety assays. For more information, visit http://www.ncardia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005200/en/



Ncardia:Steven Dublinmedia@ncardia.com

Originally posted here:
Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of...

Stem cell treatment off the table – Zululand Observer

Rhyah Govender with mom Pamela at her 7th birthday party last year

OWING to recurring infection and organ issues, Richards Bays Rhyah Sai Govender will no longer undergo stem cell treatment as planned in India.

The seven-year-old, diagnosed with cerebral palsy, was scheduled for treatment this month but recurrent urinary tract infections and problems with her kidneys have forced her family to explore other treatment avenues.

They have contacted the Bostons Children Hospital in the United States in an effort to find a panel of doctors who specialise in this condition.

Rhyahs mother, Pamela, said the family has overcome the initial disappointment and is now focused on finding another way forward.

While searching for a panel of local doctors who specialise in assisting children with cerebral palsy, a professor at one of the academic hospitals told us such a panel does not exist in our country.

Over the past seven years we have had our fair share of nightmare experiences with some doctors in the country, and we felt many used our daughter as a test subject only.

Despite the poor prognosis, Rhyah Sais family has never given up in their efforts to improve the quality of her life and she went on to defy the medical odds.

While stem cell therapy treatment will still be in the grand plan of things, acquiring a team of doctors who specialise in treating cerebral palsy children who can assess and draw up a treatment plan for Rhyah Sai, is without a doubt the best course of action.

I would like to thank everyone who helped and supported our fund-raising drives last year and for all the love and encouragement shown towards our family, said Pamela.


Like ourFacebook pageand follow us onTwitter.

For news straight to your phone invite us:

WhatsApp 072 069 4169


See the original post here:
Stem cell treatment off the table - Zululand Observer

UK biotech PhoreMost to work with Otsuka on gene therapy projects – – pharmaphorum

Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japans Otsuka working on several gene therapy projects.

Cambridge-based PhoreMost said it will use its next-generation phenotypic screening platform Siteseeker to identify novel targets for Otsukas therapeutics discovery programmes.

Novel targets identified will be further validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

Siteseeker looks at different protein shapes to find functionally active peptides that can be targeted by new therapies.

The technology looks at the entire proteome all of the proteins expressed in a live cell environment looking for druggable targets for a chosen disease.

Financial details of the agreement were not disclosed.

Dr Chris Torrance, CEO of PhoreMost, said: This collaboration with Otsuka is further recognition of the power of the Siteseeker approach to drive the identification of novel, druggable targets.

We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.

PhoreMost was one of two UK-based companies to receive funding from the government-backed agency Innovate UK to receive funding for small molecule research.

The 1 million funding was announced in 2018, and supported PhoreMost and the immune-oncology firm NeoPhore.

The companies won the funding as part of a competition organised by Innovate UK and funded by the UKs Biomedical Catalyst.

PhoreMost is also working with Indias Centre for Chemical Biology and Therapeutics, part of the Institute for Stem Cell Science and Regenerative Medicine (inStem).

The project began in July last year and, with funding from the Indian government, aims to create chemical tools that modulate novel classes of drug targets.

InStem is researching the genetic mechanisms of potency, differentiation and proliferation in human pluripotent cells.

It aims to examine diseases that can potentially be treated by stem cells.

Originally posted here:
UK biotech PhoreMost to work with Otsuka on gene therapy projects - - pharmaphorum

J&J wins another label expansion for Darzalex in Europe – PMLiVE

Johnson & Johnson, through its Janssen pharmaceutical division, has scored another label expansion in Europe for Darzalex in newly diagnosed multiple myeloma patients.

This time round, the newly approved formulation is comprised of anti-CD38 Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd),a triple regimen which is commonly used in the treatment of multiple myeloma.

The European Commission has granted a marketing authorisation for the Darzalex-VTd combination as a treatment of newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT). J&J was granted FDA approval for this Darzalex regimenlast September, in the same patient population.

The new expansion authorisation was based on results from J&Js phase 3 CASSIOPEIA trial, in which Darzalex and VTd significantly improved progression-free survival by 93% compared to 85% of those treated with VTd alone.

We asked ourselves can we improve the standard of care that is bortezomib, thalidomide and dexamethasone (VTd) to provide patients with valuable extra time? said Philippe Moreau, principal investigator and head of the haematology department at the University Hospital of Nantes, France.

The CASSIOPEIA study answered that question definitively, demonstrating that the addition of daratumumab in combination with VTd can lead to very deep remissions and also prolong PFS, he added.

The drug, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.

J&J has largely had the anti-CD38 category to itself since Darzalex was first approved in 2015, and has chalked up a number of label expansions during that time, importantly in the early stages of the disease.

This includes anothercombination regimen, with Celegenes Revlimid (lenalidomide) and dexamethasone (DRd), for the treatment of newly diagnosed multiple myeloma patients who are ineligible for ASCT.

This approval represents our commitment to investigate daratumumab in earlier disease stages of multiple myeloma and to develop more effective frontline treatment options for newly diagnosed patients who are eligible for transplantation, said Craig Tendler, vice president, clinical development and global medical affairs, oncology, Janssen Research & Development.

However, J&J could see its exclusivity disappear as Sanofis rival anti-CD38 mAb isatuximab is currently being reviewed by the FDA for the treatment of relapsed/refractory multiple myeloma with a target action date for a decision due on30 April.

J&Js expansion into the earlier settings will see it retain a large share of the market, but the encroachment of another therapy could still damage sales of the blockbuster therapy.

Originally posted here:
J&J wins another label expansion for Darzalex in Europe - PMLiVE

Mayo woman raising funds for niece, 4, who is losing her sight from three different eye conditions – Extra.ie

A Mayo woman is raising funds for her niece who is losing her sight from three different eye conditions.

Magdalena Krawiec, originally from Poland, wants to help her goddaughter Zuzia Krawiec to get the best care possible.

Zuzia, four, was born with an eye disease called congenital nystagmus, which can be caused with the eye itself or by a problem with the visual pathway from the eye to the brain.

Around four months after she was born, Zuzia was then diagnosed with hyperopia astigmatism.

The condition affects Zuzias sight so that objects close to her are out of focus.

This along with her mcular hypoplasia, which she was only diagnosed with recently, make it impossible for her to see anything in detail.

Her aunt told Extra.ie: The macular hypoplasia is the worst because theres not much we can do about it.

It affects the vision clarity and because of it she will never be able to see clearly. She can only see as far as one metre and its basically shadows and lights

Were working on her sight so that she will eventually be able to see 10 or 15 metres in front of her but thats going to be over many years.

Zuzia has to take medication and do exercises to help her eyes improve but shes also had to have surgeries.

Shes had one of ten surgeries so far and the family are looking into stem cell treatment, which more people are interested in in recent years.

The family hope to schedule her second operation soon as the masses are really loose behind her eye and they need to tighten those muslces.

This operation will held Zuzias eyeball become more steady and so help her look straight because right now theyre all over the place.

Theyre kind of shaky, Magdalena continued. Thats the problem.

Zuzia is currently in play school but once a week she goes to a special school where she does two hours of different exercises for children with disabilities.

One hour she learns how to use her hands to recognise objects and another hour Zuzia uses an optical enlarger, something her family hopes to buy her so she can see things better.

It will be able to help her see better as it makes pictures at least 50 times larger, Magdalena said.

Zuzia needs constant care, her aunt tells Extra.ie, so that she doesnt hurt herself as she walks around.

Magdalena said: She needs help going to the toilet or going outside, anything where there may be obstacles in her way.

She cant see so she could walk into a wall or something, she could hurt herself.

Zuzia will never have the same sight the average person has, but with the operations she may gain better sight.

Magdalena revealed that she and her family dont know the root of the problem and hope genetic tests will help them get an idea of what is going on.

The genetic tests have to be done through the national health service and can take two to three years, but another huge hit is the cost of the tests.

Its around 2,500, Magdalena said. Its ridiculous because shes young, we need to do it as quick as possible.

The brain is getting used to the eyes not working, so the quicker we get it fixed the better. We want her to actually see something.

Despite her eyesight, Zuzia is a happy child and a big sister to her baby brother.

However, Zuzia has started asking about her brothers sight, wondering: How come he can see and I cant?

Its heartbreaking, Magdalena admitted. Its hard to explain to her that her eyes are sick.

To help her family, Magdalena set up a GoFundMe page to raise money for Zuzias operation and her care, which you can donate to here.

Magdalena has also has a collection point in The Breadski Brothers store in Westport to help raise funds.

She really needs specialised care, especially during these early years in her development, to improve her chances of avoiding total blindness and giving her the childhood she deserves.

Read more here:
Mayo woman raising funds for niece, 4, who is losing her sight from three different eye conditions - Extra.ie

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Predicted to Grow by 2028 with Competitive Situation and Business…

The research report on Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market offers the effective objectives of the market share, growth aspects, and market segmentation. In addition, the report includes the detailed analysis for significant designing of innovative strategies for service providers. Likewise, this report also provides the collection of information which is gathered for qualitative methodologies as well as survey studied by an experienced analyst. Moreover, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report includes the comprehensive details of the market comprising market trends, growth paths, market opportunities, limitations, challenges, and leading service providers of the respective market for the prediction period.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4155718

In addition, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report delivers the fundamental analysis which is carried out by experienced analysts with a perspective of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry. Furthermore, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report also covers the structures of the industries across the globe. The research report is designed with the help of proficient standardized tools such as SWOT analysis and others. Additionally, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) report offers a brief judgement of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market. The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry report offers a broad estimation of the prediction period that will guide the users to take significant decisions over the forecasted chart. This report contain the overall analysis of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market.

Key Players Analysis:

JanssenQiagenAdvanced Cell DiagnosticsApoCellBiofluidicaClearbridge BiomedicsCytoTrackCelseeFluxionGilupiCynvenioOn-chipYZY BioBioViewFluidigmIkonisysAdnaGenIVDiagnosticsMiltenyi BiotecScreenCellSilicon Biosystems

Browse the complete report @ https://www.orbisresearch.com/reports/index/2013-2028-report-on-global-circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-by-player-region-type-application-and-sales-channel

Market split by Type:


Market split by Application:

Breast Cancer Diagnosis and TreatmentProstate Cancer Diagnosis and TreatmentColorectal Cancer Diagnosis and TreatmentLung Cancer Diagnosis and TreatmentOther Cancers Diagnosis and Treatment

Market segment by Region/Country including:

North America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Spain etc.)Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)South America Brazil, Argentina, Colombia and Chile etc.)Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

Major Points from Table of Content:

Chapter 1 Market OverviewChapter 2 Market Segment Analysis by PlayerChapter 3 Market Segment Analysis by TypeChapter 4 Market Segment Analysis by ApplicationChapter 5 Market Segment Analysis by Sales ChannelChapter 6 Market Segment Analysis by RegionChapter 7 Profile of Leading PlayersChapter 8 Upstream and Downstream Analysis of Scar DressingChapter 9 Development Trend of (2019-2028)Chapter 10 Appendix

Place a purchase order of this report @ https://www.orbisresearch.com/contact/purchase-single-user/4155718

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199 ; +91 895 659 5155

Original post:
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Predicted to Grow by 2028 with Competitive Situation and Business...

Michael Schumacher health update: Neurosurgeon claims F1 legend ‘nothing like we remember’ – Express.co.uk

The Formula One legend suffered a brain injury in December 2013 and has only just come out of an induced coma. Due to the amount of time since his injury, leading surgeon, Nicola Acciari, has warned the Formula One driver is now a different person.

The surgeon told Contro Copertina: "We must imagine a person very different from the one we remember on the track, with a very altered and deteriorated organic, muscular and skeletal structure.

"All as a result of the brain trauma he suffered."

Updates on the health of the racing legend have been kept to a minimum over the last few years.

What is known is that Michael Schumacher has been receiving groundbreaking treatment from French surgeon, Philippe Menasche.

Mr Menasche is a leading light in stem cell therapy and was reportedly using surgery to transfer cells from his heart to the brain according to Spanish publication 20minutos.

The treatment took place at the Georges-Pompidou Hospital and according to Schumacher's doctor, professor Jean-Francois Payen, he has returned this month for the same treatment.

He said: "There is a one to three-year plan for the regeneration period.

I visit Schumacher frequently and talk to his family about the progress I see.

JUST IN:Michael Schumacher latest: Fan club to mark anniversary of accident

"I saw the race together withMichael Schumacherat his home in Switzerland.

"Michael is in the best hands and is well looked after in his house.

"He does not give up and keeps fighting.

"His family is fighting just as much and of course our friendship cannot be the same as it once was just because there's no longer the same communication as before."

During his stem cell treatment, Mr Menasche was forced to defend himself over accusations he was using Schumacher as an experiment as opposed to a patient to operate on.

The professor at the University of Alabama and leader of the National Institute for Medical and Health research hit back and said: There was great attention to our department, but it has already returned to normal.

There has been great progress in the last 20 years, but the truth is that we still know little.

To mark the six-year anniversary of his injury, his wife Corinna, issued a message to his fans.

Continue reading here:
Michael Schumacher health update: Neurosurgeon claims F1 legend 'nothing like we remember' - Express.co.uk

Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position – GlobeNewswire

Press release Regulated information

Phase III study of JTA-004 in patients with knee osteoarthritis on track to start patient enrollment early 2020

CTA submission initiated for Phase IIb with ALLOB in difficult tibial fractures

Two-year follow-up Phase IIa data for ALLOB in spinal fusion expected in H2 2020

Cash burn for the full year 2019 below guidance

Gosselies, Belgium, 22January 2020, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopedics and bone diseases, today provides its business outlook for 2020 and reports its cash position for the year ending December31, 2019.

Outlook for 2020

Clinical Trial Application (CTA) for the knee osteoarthritis pivotal Phase III study with the Companys enriched protein solution, JTA-004, has been submitted to regulatory authorities in 5 European countries and Hong Kong Special Administrative Region, with patient enrollment expected to start early 2020. The JTA-004 PhaseIII study is a placebo and active-controlled, randomized, double-blind study to evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading osteoarthritis treatment on the market. The first results of the study are anticipated in the second quarter of 2021 after afollow-up period of 3 months.

The Company is initiating the CTA submission process in Europe for a PhaseIIb clinical trial with its allogeneic bone cell therapy product, ALLOB, in patients with tibial fractures at risk for delayed healing, using its optimized production process. The first patients are expected to be enrolled in Q2 2020.

In the second half of 2020, the Company expects to report results from the 2-year follow-up period of thePhaseIIa study with ALLOB in patients undergoing a spinal fusion procedure following the successful completion of the 12-months period for which positive results were published in July 2019. These results demonstrated that ALLOB in addition to the standard of care procedure was well-tolerated and resulted in significant clinical and radiological improvements.

Miguel Forte, Chief Executive Officer of Bone Therapeutics commented: I am very pleased to see that we continue to make strong progress in executing on our business strategy to become a global innovator in bone related diseases. In the next coming months, we expect to run a pivotal trial with our novel protein solution, JTA-004, with the goal to provide relevant regulatory and clinical evidence about the potential of JTA-004 as a treatment option for the many patients suffering from knee osteoarthritic pain. The anticipated start of the PhaseIIb study in patients with difficult to heal fractures and the 24months results from the PhaseIIa trial in patients undergoing a spinal fusion procedure, which we expect later this year, could further underscore the unique potential of ALLOB to bring much needed innovation to the treatment of severe bone disorders."

Cash position for the full year ended December 31, 2019

The continued strong focus on cash management resulted in a net cash utilization of 11.5million(1) for the full year 2019 which was below the Companys guidance of 12-13million. The net cash position totaled 8.6million(1) for the year ended December 31, 2019. The Company anticipates having sufficient cash to carry out its business objectives into Q3 2020.

Following the previously announced discontinuation of the autologous cell therapy program, PREOB, end 2018, Asahi Kasei and the Company agreed to formally end the PREOB licensing agreement. As a result, Bone Therapeutics and the Walloon Region agreed to terminate the related reimbursable grant agreements under the form of Recoverable Cash Advances, thereby reducing cash reimbursements and associated interest payments that were due by the Company by 1.4M over the next 5 years.

Financial Calendar 2020

The financial calendar is communicated on an indicative basis and may be subject to change.

(1) Unaudited number

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) to start the pivotal Phase III program has been submitted to the regulatory authorities in Europe and the trial is expected to start in Q1 2020.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the promising Phase IIa efficacy and safety results for ALLOB, the Company has started the CTA submission procedure with the regulatory authorities in Europe to start the Phase IIb clinical trial with ALLOB in patients with difficult-to-heal fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.


Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

See original here:
Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position - GlobeNewswire